399 related articles for article (PubMed ID: 33778723)
1. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
[TBL] [Abstract][Full Text] [Related]
4. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
Suh CH; Kim HS; Paik W; Choi C; Ryu KH; Kim D; Woo DC; Park JE; Jung SC; Choi CG; Kim SJ
Radiology; 2019 Jun; 291(3):752-762. PubMed ID: 30990380
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
6. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
7. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
[TBL] [Abstract][Full Text] [Related]
8. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T
J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
[TBL] [Abstract][Full Text] [Related]
10. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Neuro Oncol; 2018 Nov; 20(12):1573-1583. PubMed ID: 30020513
[TBL] [Abstract][Full Text] [Related]
11. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y
Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
14. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
[TBL] [Abstract][Full Text] [Related]
15. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
16. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
Li X; Strasser B; Jafari-Khouzani K; Thapa B; Small J; Cahill DP; Dietrich J; Batchelor TT; Andronesi OC
Radiology; 2020 Mar; 294(3):589-597. PubMed ID: 31909698
[TBL] [Abstract][Full Text] [Related]
17. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
[TBL] [Abstract][Full Text] [Related]
18. Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
An Z; Tiwari V; Ganji SK; Baxter J; Levy M; Pinho MC; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
Magn Reson Med; 2018 Apr; 79(4):1851-1861. PubMed ID: 28833542
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
20. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
